Author: s.mengoni@pensiero.it

Gallois C, et al. Background: The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E mutated metastatic colorectal cancer (mCRC), after a prior systemic therapy. This retrospective study aims to describe the efficacy and safety of encorafenib with cetuximab combination in the real-world setting. Methods: All consecutive patients...

Punt CJA, Bond MJG, Bolhuis K, et al. Background: CAIRO5 aimed to find the optimal systemic induction regimen to convert initially unresectable CRLM to local treatment.Previously, we showed that for patients with right-sided and/or RAS/BRAFV600E mutated tumours PFS was significantly longer and complete local treatment (R0/R1 resection and/or ablation) higher with FOLFOXIRI vs FOLFOX/FOLFIRI, both...

Pietrantonio F, Salvatore L, Esaki T, et al. Background: We report the first Phase 3 primary results for sotorasib (soto), a KRASG12C-inhibitor, plus panitumumab (pani), an anti-EGFR antibody, vs standard of care (SOC) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC. Methods: In the CodeBreaK 300 (NCT05198934) global, open label study, 160 pts with chemorefractory...

Ghidini M, Hahne JC ,  Senti C, et al. Background: The potential of monitoring circulating tumor DNA (ctDNA) dynamics to guide clinical decisions in metastatic colorectal cancer patients treated with I and II line systemic anti-cancer therapy (SACT) has not been widely tested. Methods: 862 serial plasmas were collected 4-weekly from baseline (BL) until disease...

Liposits G Winther SB, Ryg J, et al. Colorectal cancer is common, with the highest incidence and mortality rate observed in adults ≥70 years [1]. Through the past decades,survival has substantially improved in young and fit patients with metastatic colorectal cancer (mCRC) eligible for intensive treatment including chemotherapy combinations (doublet/triplet) and monoclonal antibodies, e.g., vascular...

Bekaii-Saab T, Ahn D, Yuan C, et al. Background: REG and TAS are approved for the treatment of refractory mCRC. However, data on their sequential use in any setting is limited. The aim of this study was to describe the characteristics and clinical outcomes of patients (pts) with mCRC treated sequentially in community clinical practice...

Elena Elez E, Kopetz S, Tabernero J, et al. Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment...

Rasola C, Laurent-Puig P, André T, et al. Background: It is intuitively thought that early relapse is associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never been formally studied. Methods: We pooled data from stage III patients treated with oxaliplatin-based adjuvant therapy in two phase III trials,...

Sunakawa Y, Shiozawa M, Watanabe T, et al. Background: The DEEPER trial, which evaluated m-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2) plus cetuximab (cet) vs. bevacizumab (bev) as initial treatment in terms of depth of response (DpR) as the primary endpoint in RAS wild-type mCRC, has demonstrated a significantly better DpR of...